Logo image of CYTH

CYCLO THERAPEUTICS INC (CYTH) Stock Fundamental Analysis

USA - NASDAQ:CYTH - US23254X2018 - Common Stock

0.7206 USD
+0.01 (+1.39%)
Last: 3/25/2025, 8:00:01 PM
0.7199 USD
0 (-0.1%)
After Hours: 3/25/2025, 8:00:01 PM
Fundamental Rating

2

CYTH gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. Both the profitability and financial health of CYTH have multiple concerns. CYTH is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CYTH had negative earnings in the past year.
CYTH had a negative operating cash flow in the past year.
CYTH had negative earnings in each of the past 5 years.
In the past 5 years CYTH always reported negative operating cash flow.
CYTH Yearly Net Income VS EBIT VS OCF VS FCFCYTH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M -20M

1.2 Ratios

Looking at the Return On Assets, with a value of -472.02%, CYTH is doing worse than 96.65% of the companies in the same industry.
Industry RankSector Rank
ROA -472.02%
ROE N/A
ROIC N/A
ROA(3y)-196.91%
ROA(5y)-167.39%
ROE(3y)-876.42%
ROE(5y)-703.18%
ROIC(3y)N/A
ROIC(5y)N/A
CYTH Yearly ROA, ROE, ROICCYTH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -500 -1K -1.5K -2K

1.3 Margins

CYTH's Gross Margin of 91.24% is amongst the best of the industry. CYTH outperforms 91.90% of its industry peers.
CYTH's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for CYTH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 91.24%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.5%
GM growth 5Y0.39%
CYTH Yearly Profit, Operating, Gross MarginsCYTH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

More info and screens

0

2. Health

2.1 Basic Checks

CYTH does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CYTH has been increased compared to 1 year ago.
Compared to 5 years ago, CYTH has more shares outstanding
There is no outstanding debt for CYTH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CYTH Yearly Shares OutstandingCYTH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
CYTH Yearly Total Debt VS Total AssetsCYTH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M

2.2 Solvency

CYTH has an Altman-Z score of -45.56. This is a bad value and indicates that CYTH is not financially healthy and even has some risk of bankruptcy.
CYTH's Altman-Z score of -45.56 is on the low side compared to the rest of the industry. CYTH is outperformed by 93.13% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -45.56
ROIC/WACCN/A
WACC10.15%
CYTH Yearly LT Debt VS Equity VS FCFCYTH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M

2.3 Liquidity

CYTH has a Current Ratio of 0.17. This is a bad value and indicates that CYTH is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of CYTH (0.17) is worse than 96.48% of its industry peers.
CYTH has a Quick Ratio of 0.17. This is a bad value and indicates that CYTH is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.16, CYTH is doing worse than 96.30% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.17
Quick Ratio 0.16
CYTH Yearly Current Assets VS Current LiabilitesCYTH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 44.87% over the past year.
The Revenue has decreased by -8.86% in the past year.
The Revenue has been growing slightly by 1.28% on average over the past years.
EPS 1Y (TTM)44.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.34%
Revenue 1Y (TTM)-8.86%
Revenue growth 3Y6.15%
Revenue growth 5Y1.28%
Sales Q2Q%-52.98%

3.2 Future

CYTH is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.87% yearly.
The Revenue is expected to grow by 106.48% on average over the next years. This is a very strong growth
EPS Next Y56.84%
EPS Next 2Y25.49%
EPS Next 3Y20.87%
EPS Next 5YN/A
Revenue Next Year-41.47%
Revenue Next 2Y-14.64%
Revenue Next 3Y106.48%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CYTH Yearly Revenue VS EstimatesCYTH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 5M 10M
CYTH Yearly EPS VS EstimatesCYTH Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 -2 -4 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CYTH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CYTH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CYTH Price Earnings VS Forward Price EarningsCYTH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CYTH Per share dataCYTH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

CYTH's earnings are expected to grow with 20.87% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.49%
EPS Next 3Y20.87%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CYTH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CYCLO THERAPEUTICS INC

NASDAQ:CYTH (3/25/2025, 8:00:01 PM)

After market: 0.7199 0 (-0.1%)

0.7206

+0.01 (+1.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-25 2025-03-25/amc
Earnings (Next)05-13 2025-05-13
Inst Owners11.45%
Inst Owner Change0%
Ins Owners8.13%
Ins Owner Change0%
Market Cap23.72M
Revenue(TTM)870.80K
Net Income(TTM)-24.80M
Analysts77.78
Price Target0.97 (34.61%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-50.89%
Min EPS beat(2)-68.96%
Max EPS beat(2)-32.83%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-38.61%
Min Revenue beat(2)-54.92%
Max Revenue beat(2)-22.3%
Revenue beat(4)0
Avg Revenue beat(4)-39.05%
Min Revenue beat(4)-54.92%
Max Revenue beat(4)-22.3%
Revenue beat(8)1
Avg Revenue beat(8)-43.22%
Revenue beat(12)2
Avg Revenue beat(12)-33.37%
Revenue beat(16)3
Avg Revenue beat(16)-29.66%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 27.24
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.92
EYN/A
EPS(NY)-0.68
Fwd EYN/A
FCF(TTM)-0.68
FCFYN/A
OCF(TTM)-0.68
OCFYN/A
SpS0.03
BVpS-0.41
TBVpS-0.41
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -472.02%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 91.24%
FCFM N/A
ROA(3y)-196.91%
ROA(5y)-167.39%
ROE(3y)-876.42%
ROE(5y)-703.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.5%
GM growth 5Y0.39%
F-Score3
Asset Turnover0.17
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.17
Quick Ratio 0.16
Altman-Z -45.56
F-Score3
WACC10.15%
ROIC/WACCN/A
Cap/Depr(3y)70.81%
Cap/Depr(5y)142.49%
Cap/Sales(3y)0.98%
Cap/Sales(5y)1.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.34%
EPS Next Y56.84%
EPS Next 2Y25.49%
EPS Next 3Y20.87%
EPS Next 5YN/A
Revenue 1Y (TTM)-8.86%
Revenue growth 3Y6.15%
Revenue growth 5Y1.28%
Sales Q2Q%-52.98%
Revenue Next Year-41.47%
Revenue Next 2Y-14.64%
Revenue Next 3Y106.48%
Revenue Next 5YN/A
EBIT growth 1Y-27.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-50.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-50.22%
OCF growth 3YN/A
OCF growth 5YN/A

CYCLO THERAPEUTICS INC / CYTH FAQ

What is the ChartMill fundamental rating of CYCLO THERAPEUTICS INC (CYTH) stock?

ChartMill assigns a fundamental rating of 2 / 10 to CYTH.


What is the valuation status of CYCLO THERAPEUTICS INC (CYTH) stock?

ChartMill assigns a valuation rating of 1 / 10 to CYCLO THERAPEUTICS INC (CYTH). This can be considered as Overvalued.


Can you provide the profitability details for CYCLO THERAPEUTICS INC?

CYCLO THERAPEUTICS INC (CYTH) has a profitability rating of 1 / 10.


Can you provide the financial health for CYTH stock?

The financial health rating of CYCLO THERAPEUTICS INC (CYTH) is 0 / 10.